Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant
There was no significant difference in transplant-related mortality or overall survival.
Acute Lymphoblastic Leukemia
Patterns of Resistance to CAR-T Therapy in Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.
Risks for Relapse Revealed in Multiethnic Study of Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine risk factors for relapse in patients with ALL.
Blinatumomab Effective in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia
Researchers sought to determine whether blinatumomab followed by POMP maintenance chemotherapy would be safe and effective in older patients with B-ALL.
Drugs in Phase 1 Trials Becoming More Effective, No Less Fatal
Response rates improved from 2000 to 2019, but the rate of treatment-related fatal toxicities remained stable.
Bortezomib Improves EFS, OS in T-Cell Lymphoblastic Lymphoma
Bortezomib improved event-free survival and overall survival in children and young adults with T-cell lymphoblastic lymphoma.
Blinatumomab as Rescue Therapy in Relapsed/Refractory B-ALL
About 62% of patients achieved a complete response, and this included patients with high-risk cytogenetics.
Survival Increase Seen for Adults With Relapsed Ph+ ALL
From 2000 to 2019, overall survival progressively improved for patients with Ph+ ALL who had post-transplant relapse.
Inotuzumab Ozogamicin Deemed Effective in Heavily Pretreated B-ALL
The estimated event-free survival rate was 28.6% at 2 years and 19.6% at 3 years.
Platelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic Malignancies
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...